Kornimate/medical-research-clean huggingface dataset:
guanidinoacetic acid with creatine compared with creatine alone for tissue bioenergetics, hyperhomocysteinemia and exercise performance

Conditions: Energy Metabolism

Summary: co-administration of creatine and guanidinoacetic acid (gaa) has been recently put forward as an advanced dietary strategy to optimize tissue bioenergetics. the investigators hypothesized that creatine-gaa mixture would result in more powerful rise in brain and skeletal muscle creatine, as compared to creatine supplementation alone.

targeting energy-demanding tissues in health and disease continues to be a challenging task in human nutrition and biomedicine. impaired bioenergetics accompanies many different conditions, including cardiometabolic diseases, neurodegenerative disorders or high-intensity exercise, with various dietary interventions developed to restore cellular energy. creatine is recognized as a beneficial and safe energy-boosting agent in both athletic and clinical environments. however, its effectiveness in specific conditions seems to be fairly restrained due to its limits in transportability and performance. guanidinoacetic acid (gaa), a metabolic precursor of creatine, appears as a novel energy-enhancing supplement, with gaa being superior to creatine in facilitating creatine concentrations in the human brain and skeletal muscle. this perhaps happens due to gaa interaction with cellular transporters previously dismissed as untargetable carriers by other similar therapeutics. on the other hand, gaa loading remains under scrutiny due to its hyperhomocysteinemia-inducing potential, and possible neurotoxic effects. co-administration of creatine and gaa has been recently proposed as a better strategy comparing to administration of each compound per se. besides providing a competitive advantage for enhanced levels of tissue creatine, gaa-creatine mixture might also diminish side effects related to isolated gaa administration. however, no human studies so far evaluated the effects of this mixture. in the present study, the investigators compared the impact of 4-week co-administration of gaa and creatine vs. creatine administration alone on serum biomarkers, exercise performance and tissue bioenergetics in healthy young men.

Eligibility criteria:
inclusion criteria: * men age 18-45 years * bmi 18.5-24.9 kg/m2 * physically active (\> 150 min per week) * free of known disease * must be able to give written informed consent exclusion criteria: * serum homocysteine \> 15 µmol/l * use of dietary supplement (\> 1 month)
maintenance therapy with anti-pd-1 antibody for patients with nk/t-cell lymphoma

Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type

Summary: for patients with nk/t-cell lymphoma, plasma ebv-dna has been found to be a prognostic factor, and those with positive plasma ebv-dna at the end of treatments are more likely to suffer from disease relapse. thus, this study aims to evaluate the role of maintenance with anti-pd-1 antibody.

for patients with nk/t-cell lymphoma, plasma ebv-dna has been found to be a prognostic factor, and those with positive plasma ebv-dna at the end of treatments are more likely to suffer from disease relapse. the investigators previously reported one-year progression free survival rate of 22.2% for patients with positive plasma ebv-dna at the end of treatments. recently, anti-pd-1 antibody has been shown to be highly effective in the treatment of nk/t-cell lymphoma. thus, this study aims to evaluate the role of maintenance with anti-pd-1 antibody for patients with positive plasma ebv-dna at the end of treatments.

Eligibility criteria:
inclusion criteria: * pathology confirmed diagnosis of nk/t-cell lymphoma. * plasma ebv-dna was positive at the end of first-line pegaspargase-based regimens. * ecog score of 0-3 points. * the lab tests within 1 week before enrollment meets the following: * blood routine: hb≥80g/l, plt≥50×10e9/l. * liver function: alt, ast, tbil≤2 times the upper limit of normal. * renal function: cr is normal. * coagulation: plasma fibrinogen≥1.0g/l. * cardiac function: lvef≥50%, ecg is normal * sign the informed consent form. * voluntary compliance with research protocols. exclusion criteria: * patients had relapsed nk/t-cell lymphoma. * active infection requires icu treatment. * concomitant hiv infection or active infection with hbv, hcv. * serious complications such as fulminant dic. * significant organ dysfunction: * respiratory failure * nyha classification≥2 chronic congestive heart failure * decompensation hepatic or renal insufficiency * high blood pressure and diabetes that cannot be controlled * cerebral vascular events within the past 6 months. * pregnant and lactating women. * had a history of autoimmune diseases, and disease was active now. those who were known to be allergic to drugs in the study regimen. * patients with other tumors who require treatments within 6 months. * other experimental drugs are being used.

Keywords: extranodal nk/t-cell lymphoma pd-1 blockade maintenance therapy
the role of the coagulation pathways in recurrent angioedema

Conditions: Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency

Summary: previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. this study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways.

previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. this study aim to compare groups with isolated wheals, isolated angioedema, combination of both and hereditary angioedema in terms of coagulation pathways. the main objective is to highlight a difference between the rates of different coagulation factors in the 3 groups presenting different categories of angiodemes patients with a group of patients with isolated superficial chronic urticaria

Eligibility criteria:
inclusion criteria: * recurrent angioderma exclusion criteria: * anticoagulant therapy, diseases of hemostasis
investigation of novel procedure for methacholine challenge testing

Conditions: Asthma

Summary: the study will compare a novel volumetric method (performed with the aerogen solo vibrating mesh nebulizer) with the standard two-minute tidal breathing protocol (performed with the wright jet nebulizer) for methacholine challenge testing. the results will then give an indication as to whether the novel technique accurately assesses a given dose of methacholine with the new aerogen solo device. in addition, the reproducibility of test results with each method will be examined. altogether, the findings from this investigation may provide means for better standardization of current testing guidelines.

fifteen asthmatics will be recruited and tested at the university of saskatchewan for this randomized, two-way crossover study. two testing methodologies will be performed, the volumetric method with the aerogen solo nebulizer and the two-minute tidal breathing method with the wright nebulizer. participants will undergo four methacholine challenges plus a screening methacholine challenge. however, screening is omitted with participants who have completed a methacholine challenge in the last six months. of the four study challenges, two will utilize the wright nebulizer with the two-minute tidal breathing method outlined in the 1999 american thoracic society guidelines for methacholine challenge testing. the remaining two challenges will utilize the aerogen solo nebulizer with the volumetric method. the timing of the spirometric manoeuvers and the duration of each inhalation cycle will be consistent with both testing methods. each challenge will be stopped when the participant's forced expiratory volume in 1 second (fev1) drops by at least 20%. this allows determination of apc20 (provocative concentration of methacholine causing a 20% fall in fev1), which will be converted to apd20 (provocative dose). a minimum 24-hour washout period between challenges will be used.

Eligibility criteria:
inclusion criteria: * men and women aged 18 or older * stable asthma * baseline methacholine pc20 less than or equal to 16mg/ml * baseline lung function equal or greater than 65% of predicted fev1 exclusion criteria: * use of long-acting bronchodilators within 7 days of visit 1 * pregnant or nursing women * cardiovascular problems * upper respiratory tract infection within 4 weeks of visit 1 * allergy-induced asthma exacerbation within 4 weeks of visit 1

Keywords: methacholine, airway hyperresponsiveness
body image satisfaction in relation to body mass index and self- esteem among chinese female students

Conditions: Healthy

Summary: body image satisfaction and self- esteem level are important to be known among students in order to intervene in a correct time. body dissatisfaction is one of the factors leading to negative self-perception, low mood, depression, and eating disorders. this may be detrimental to students in their academic performance. however, the correlations of body image satisfaction towards body mass index and self- esteem among university female students are still unclear in malaysia. thus, the purpose of this study is to determine its relationships among chinese female students. university female participants will be included with convenience sampling method. participants will completed ronsenberg self- esteem scale and 8 items version of body shape questionnaire. these 2 scales used to measure level of self- esteem and body image satisfaction. body mass index will be calculated from self- reported height and weight. the data will be analysed by using descriptive and correlation methods.


Eligibility criteria:
inclusion criteria: * female and chinese students * age more or equal than 20 years ( ≥20 ) * utar students exclusion criteria: * male and non-chinese students * age less than 20 ( \<20 ) * non- utar students

Keywords: self esteem body mass index
confocal laser endomicrospy in colonic diverticular disease

Conditions: Diverticular Disease; Diverticulitis; Diverticula

Summary: confocal laser endomicroscopy detects inflammatory markers undetectable during high definition endoscopy. the investigators aimed to evaluate the role of peridiverticular and colonic mucosa inflammation in the prediction of the complicated diverticular disease using confocal laser endomicroscopy evaluation in the peridiverticular area in consecutive patients.

diverticular disease of the colon is a prevalent condition in the western hemisphere. currently there is an endoscopic classification system for classifying diverticular disease; however, white light endoscopic fails to accurately detect inflammation. confocal laser endomicroscopy offers a real-time, in-vivo evaluation of the colonic mucosa, with an adequate correlation to histological findings. the investigators aimed to evaluate the role of peridiverticular and colonic mucosa inflammation in the prediction of complicated diverticular disease.

Eligibility criteria:
inclusion criteria: * above 18 years old * writeen informed consent provided. * endoscopic visualization of diverticular disease during colonoscopy. * adequate bowel preparation bbps \>2 in each colon segment exclusion criteria: * under 18 years old. * refuse to sign written informed consent. * pregnancy or nursing. * previous colorectal surgery * history of colorectal cancer * known allergy to fluorscein * uncontrolled coagulopathy * history of complicated diverticular disease * patients with inflammatory bowel disease * patients with severe comorbidities: kidney and liver failure * nsaids and antibiotics two weeks prior enrollment * historyh of alcohol or drug abuse * patients with severe mental illness * patients with incomplete evaluation of the colon

Keywords: colonoscopy diverticular disease
the clinical study on the treatment of ssc with utaa91 injection.

Conditions: Systemic Sclerosis (SSc)

Summary: this clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of utaa91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.


Eligibility criteria:
inclusion criteria: * aged ≥18 years (inclusive of the boundary value), with no restriction on gender. expected survival time of ≥3 months. refractory moderate - to - severe active systemic sclerosis that has failed standard treatment or lacks effective therapeutic options. meets the requirements for liver and kidney function, as well as cardiopulmonary function. free from severe psychiatric disorders. able to understand the trial and has signed the informed consent form. exclusion criteria: * a history of malignant tumors other than relapsed/refractory autoimmune diseases (r/r aid) within 5 years prior to screening. positive results in virology/syphilis tests. severe cardiac diseases or unstable systemic diseases. presence of active or uncontrollable infections requiring systemic treatment, or evidence of central nervous system invasion. pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion. subjects who have received car - t therapy or other gene - modified cell therapies prior to screening. subjects who participated in other clinical studies within 1 month prior to screening. other conditions deemed unsuitable for enrollment by the investigator.
remifemin preventing the climacteric symptoms in breast cancer

Conditions: Effect of Drugs; Safety Issues

Summary: lhrh-a is an important hormone treatment in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. the climacteric symptoms caused by lhrh-a are often and prominent, which is a common clinical problem.

ovarian function suppression (ofs) or protection has been studied widely in breast cancer. as an common drug in clinic, lhrh-a is an important method for ofs in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. the climacteric symptoms caused by lhrh-a are often and prominent, which is a common clinical problem. remifemin (cimicifuga racemosa / black cohosh) is effective in climacteric symptoms as a hormone replacement treatment, some research concluded that it is also safe in breast cancer patients who are postmenopausal or taking tamoxifen suffering from climacteric symptoms. while in china, more than 2/3 breast cancer patients are pre/peri-menopause, and some part of them should take ofs as an hormone treatment. ofs can cause sever climacteric symptoms in a short time. the investigators aim to estimate the effect and safety of remifemin in climacteric symptoms caused by ofs in breast cancer.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent 2. clinical stage i\~iiic 3. histologically proven invasive breast cancer 4. women defined as premenopausal according to nccn guideline 5. plan to accept the lhrh-a as endocrine treatment or ovarian function protection exclusion criteria: 1. clinical evidence of metastatic disease 2. bilateral oophorectomy 3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements 4. patients who accepted anti-cancer treatment before 5. previous hormonal therapy as adjuvant treatment for non-cancer disease 6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied 7. treatment with a non-approved or experimental drug during 1 month before entry into the study 8. history of bleeding diathesis (i.e., disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin) 9. leukopenia and/or thrombocytopenia 10. history of ocular fundus diseases 11. history of thromboembolic diseases 12. history of osteoporotic fractures

Keywords: remifemin preventive effect lhrh-a breast cancer
covid-19 virtual care at home

Conditions: Covid-19

Summary: this multicentre prospective cohort trial is designed to demonstrate effectiveness and efficiency of a virtual care model for the management of covid-19 patients isolating at home. the investigators have reoriented existing technology and networks for this research project. the investigators are amplifying our existing virtual care platform virtues, combining it with home monitoring of covid-19 patients, to provide real-time evidence, harmonize data collection, and share data provincially to mitigate the impact of the rapid spread of the virus. the study will facilitate early detection of complications associated with the disease, treatment and management of covid-19 patients at home. the research will be conducted provincially in ontario. this initiative will provide evidence to inform clinical and health system management and public health response to covid-19 patients isolating at home.


Eligibility criteria:
inclusion criteria: * all covid-19 positive patients of age 18 or above * participant must communicate in english or french language * an email address and account exclusion criteria: * unable or unwilling to provide informed consent

Keywords: covid-19 sars-cov-2 virtues virtual care management virtual care patient satisfaction anxiety emergency visits oxygen saturation quality of life
behavioral and cognitive predictors of persistent pain and opioid misuse in chronic pain

Conditions: Chronic Back Pain

Summary: chronic lower back pain (clbp) affects approximately 20% of the global population. the study objective is to determine if impulsivity, inhibitory control, drug choice, and/or cognitive distortions predict opioid misuse and disability in patients with chronic pain. this is a prospective consented cross-sectional study characterizing behavioral and cognitive phenotypes using both patient-reported survey measures and cognitive testing. outcome measures include correlations between impulsivity measures, opioid drug choice responses and cognitive distortion scores, and risk for opioid misuse (primary outcomes: comm scores, soappr scores). secondary outcomes is bpi measurement. a certificate of confidentiality will provide additional protections for participants.


Eligibility criteria:
inclusion criteria: * with diagnoses related to chronic lower back pain * age above 18yrs * non pregnant exclusion criteria: * cancer pain
evaluation of the impact of psychological profile on diabetic foot wound healing. prospective, monocentric study

Conditions: Type 2 Diabetes; Foot Wound

Summary: foot wounds in patients with diabetes are one of the most frequent complications associated with diabetes. despite the progress made in its management in recent years, the risk of amputation remains high in cases of diabetic foot wounds. several studies have highlighted the value of analyzing the psychological profile a or b, defined by self-questionnaire using bortner's method. the a personality profile is characterized by hyperactivity, combativeness and exaggerated ambition, while the b profile is characterized by less sensitivity to stress and reduced combativeness. type a personality profile is associated with reduced cardiovascular mortality in type 1 diabetes. type b personality profiles have also been shown to be associated with inflammation in both type 1 and type 2 diabetes. our group showed that patients with diabetes and a foot wound were more likely to have a type b psychological profile than patients with diabetes and no foot wound. however, to our knowledge, it has never been determined whether the psychosomatic profile type a or b assessed by the bortner self-questionnaire influenced wound healing and the risk of amputation. the aim of this study is to determine whether type a or b psychosomatic profile influences wound healing in diabetic feet. this study will be carried out in the endocrinology, diabetology and nutrition department of the dijon bourgogne university hospital. 308 patients will be included in the study.


Eligibility criteria:
inclusion criteria: * person who has given his non-opposition * person over 18 years of age * person with type 2 diabetes * person referred for management of a new diabetic foot wound exclusion criteria: * person subject to a legal protection measure (curatorship, guardianship) * person subject to a legal protection measure * pregnant women, women in labour or breastfeeding mothers * an adult who is incapable or unable to give consent * minors * person unable to complete self-questionnaires
study evaluating the effect of ima-026 on allergen-induced late asthma response in mild asthma

Conditions: Asthma

Summary: the purpose of this study is to evaluate the effect of ima-026, an antibody to il-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. ima-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. the study will include a screening period and a treatment period which includes doses on day 1 and day 8.


Eligibility criteria:
inclusion criteria: 1. healthy men and women 18 to 60 yrs with mild allergic asthma 2. only asthma med is short-acting bronchodilator used not more than twice weekly 3. fev1 greater than 70% predicted and a demonstrated baseline late response to allergen induction exclusion criteria: 1. upper respiratory infection or asthma exacerbation with 4 weeks of screening 2. serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of test article administration 3. positive radiographic findings indicative of respiratory disease other than asthma
evaluation of use of diagnostic ai for lung cancer in practice

Conditions: Lung Cancer

Summary: this study investigates ways of improving radiologists performance of the classification of ct-scans as cancerous or non-cancerous. participants interact with an ai to classify ct-scans under three different conditions.

the three conditions are as follows: "probabilistic classification", where the radiologist diagnoses scans using an ai cancer likelihood score; "classification plus detection", where the radiologist see detecting lung nodules in addition to the ai's probabilistic classification score before making her own examination of the ct-scan; and "classification with delayed detection", where the radiologist identifies regions of interest independently of the ai and then sees the ai's detected rois.

Eligibility criteria:
inclusion criteria: * the participant performs radiology screenings professionally exclusion criteria: -